Issues related to Alzheimer's disease and dementia, including screening, diagnosis, and care. Issues related to postpartum depression screening, detection, and education. Issues related to ALS, lupus, and kidney disease policy.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Client
- BIOGEN, INC.
- Filing UUID
- f23c88a7-0646-4e38-bd9d-18d69e018d06
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
IRA implementation. Issues related to drug pricing. 340B Program. Supply Chain. Issues related to patient affordability and access including copay and coverage reform. Issues related to PBM reform. PDUFA, drug reviews, approval pathways, PPRV Program, clinical trials. Issues related to rare diseases, including the Orphan Drug and ORPHAN CURES Act, rare disease research and screening, and patient access to therapies.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.